Raptamer Discovery Group uses our innovative, non-SELEX process, which has been developed and refined over the past two decades by leaders in the aptamer field. We conduct a fast, single-round selection against your targets using our proprietary library.

Raptamer Discovery Group uses next-generation sequencing technology to identify the nucleotide sequencing in each Raptamer™ candidate, and we use this information and our library data to identify the complete chemical structure, including side chains.

Using our sophisticated bioinformatics platform, we rank Raptamer™ candidates by their predicted performance. We have a good sense of candidate quality at this point, and will give you feedback on how the process is going.

We synthesize the highest-ranked Raptamer™ candidates for each target at a 50 nmol scale for use in our internal binding studies.

We test each of the Raptamer™ candidates for binding against your target using the sophisticated ForteBio Octet Red biomolecular interaction platform. We share these results with you to decide which candidates you want made at a medium scale.

We synthesize up to 4 candidates at 2 μmol scale, and prepare vials for shipping to you for use in the next steps of your development process.